ACADIA Pharmaceuticals Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; the filing was signed February 26, 2015. The requested “2014 Q4” figures below are the fourth-quarter results within this annual report.
Business context and development status
ACADIA was a clinical-stage biopharmaceutical company focused on neurological and central nervous system disorders, with no approved products or product-sale revenue. Its lead candidate, pimavanserin (NUPLAZID), had completed a positive Phase III pivotal study for Parkinson’s disease psychosis (PDP). The FDA granted Breakthrough Therapy designation in 2014; ACADIA planned to submit an NDA in the first quarter of 2015. Other programs included a Phase II Alzheimer’s disease psychosis study, planned further schizophrenia studies, and Allergan-partnered chronic pain and glaucoma programs. ACADIA held worldwide commercialization rights to pimavanserin.
Financial results and liquidity
| Metric | 2014 | 2013 | 2014 Q4 | 2013 Q4 |
|---|---|---|---|---|
| Revenue | $0.12 million | $1.145 million | $47,000 | $37,000 |
| Research and development expense | $60.602 million | $26.722 million | Not provided by quarter | Not provided by quarter |
| General and administrative expense | $32.748 million | $12.720 million | Not provided by quarter | Not provided by quarter |
| Net loss | $92.475 million | $37.948 million | $28.366 million | $12.049 million |
| Basic and diluted loss per share | $0.95 | $0.44 | $0.28 | $0.13 |
| Net cash used in operating activities | $66.434 million | $31.769 million | Not provided by quarter | Not provided by quarter |
- Annual revenue was entirely collaborative and grant-related; ACADIA reported no product sales. Revenue fell from 2013 as the Allergan research collaboration ended and grant activity declined.
- R&D costs rose primarily from external development spending on pimavanserin and growth in personnel and stock-based compensation. G&A rose with additional administrative and commercial staffing, stock compensation, and pre-commercial consulting and professional costs.
- At year-end, cash and cash equivalents were $61.854 million and available-for-sale investment securities were $260.632 million, totaling $322.486 million, versus $185.790 million a year earlier. Working capital was $308.784 million; total assets were $325.458 million.
- Management expected existing cash and investments to fund planned operations at least into the second half of 2016, while warning that additional financing might be needed. Net cash provided by financing activities was $203.851 million, including $196.8 million of net proceeds from a March 2014 public offering.
- The balance sheet reported no long-term debt. Total liabilities were $15.969 million, including $15.834 million of current liabilities. No meaningful product gross margin was reported because the company had no product sales.
Material changes versus the prior comparable period
- Annual net loss increased to $92.475 million from $37.948 million; Q4 net loss increased to $28.366 million from $12.049 million.
- Annual R&D expense increased to $60.602 million from $26.722 million, while G&A increased to $32.748 million from $12.720 million. Collaborative revenue declined to $120,000 from $1.145 million.
- Cash, cash equivalents, and investments increased by $136.696 million year over year, chiefly supported by the 2014 equity offering; common shares outstanding increased from 91.103 million to 100.047 million.
- Operating cash use rose to $66.434 million from $31.769 million. ACADIA attributed this mainly to the higher net loss, partly offset by non-cash stock compensation and increases in accounts payable and accrued expenses.
Outlook, risks, and contingencies
- Management expected operating losses and substantial R&D and pre-commercial spending to continue for at least several years; it did not provide revenue, earnings, or product-launch guidance. Timing and cost of development and approval could not be estimated with certainty.
- NUPLAZID’s NDA remained subject to FDA review of the full filing, manufacturing and quality systems, and other materials; Breakthrough designation and prior FDA feedback did not assure filing acceptance or approval. Commercial success, payer coverage, pricing, and physician adoption were uncertain.
- ACADIA had no product-launch experience, relied on third parties for manufacturing, and reported a single supplier for NUPLAZID active ingredient and a single tablet supplier. Commercial-scale manufacturing readiness and supply continuity were material risks.
- Allergan’s announced restructuring and pending acquisition by Actavis could affect partnered chronic pain and glaucoma programs. Future collaboration payments depended on product advancement; ongoing Allergan agreements could be terminated on notice.
- Cash runway depended on spending, development outcomes, and commercialization costs. If financing were unavailable on acceptable terms, ACADIA might delay or reduce programs or relinquish product rights; additional equity financing could dilute shareholders.
- Contractual commitments included $7.361 million of operating lease payments and up to approximately $16.3 million of future external-service obligations, generally terminable on short notice. Potential Ipsen payments included $2.5 million on successful FDA NDA filing and $8.0 million on first FDA approval, plus royalties of up to 2% of future net sales.
- Other key risks included clinical-trial failure, regulatory restrictions or post-approval requirements, reimbursement and price controls, intellectual-property challenges, product liability, and volatility in the common stock. Management and the auditor reported effective internal control over financial reporting; no material legal proceeding was identified in the supplied filing text.
Important facts for investors to verify
- Whether and when the planned NUPLAZID NDA was submitted, accepted for filing, and ultimately acted on by the FDA, including any label, safety, manufacturing, or post-marketing conditions.
- Subsequent cash burn, financing, dilution, and whether the stated runway assumptions remained valid as launch and development spending increased.
- Clinical progress and results in Alzheimer’s disease psychosis, schizophrenia, and sleep-related studies, and whether the Allergan collaborations continued after the proposed acquisition and restructuring.
- Commercial supply readiness, payer coverage and reimbursement, pricing, and physician uptake if approved.
- Potential Ipsen milestones and royalties, as well as the extent to which collaboration and grant revenue can support operations before product sales.